Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00811889 | Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease | PHASE2 | COMPLETED | 227 | — | — | Apr 30, 2009 | Dec 31, 2010 | May 29, 2025 | 42 | United States |
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| Bardoxolone Methyl (RTA 402): 75mg | EXPERIMENTAL | - |
| Bardoxolone Methyl (RTA 402): 150mg | EXPERIMENTAL | - |
| Bardoxolone Methyl (RTA 402): 25mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | OTHER | Placebo |
| Bardoxolone Methyl (RTA 402) | DRUG | Oral, Once Daily |
Inclusion Criteria: 1. Male or female patient, at least 18 years of age with known type 2 diabetes, diagnosis of type 2 diabetes should have been made at \> 30 years of age (if diabetes developed at a younger age, C-peptide level may be obtained to confirm diagnosis) 2. The average of two eGFR valu...